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Introduction: Epithelial circulating tumor cells (CTCs) are detect-
able in patients with non-small cell lung cancer (NSCLC). However,
epithelial to mesenchymal transition, a widely reported prerequisite
for metastasis, may lead to an underestimation of CTC number. We
compared directly an epithelial marker-dependent (CellSearch) and
a marker-independent (isolation by size of epithelial tumor cells
[ISET]) technology platform for the ability to identify CTCs. Mo-
lecular characteristics of CTCs were also explored.
Methods: Paired peripheral blood samples were collected from 40
chemona¨ive, stages IIIA to IV NSCLC patients. CTCs were enu-
merated by Epithelial Cell Adhesion Molecule-based immunomag-
netic capture (CellSearch, Veridex) and by filtration (ISET, RareCell
Diagnostics). CTCs isolated by filtration were assessed by immu-
nohistochemistry for epithelial marker expression (cytokeratins,
Epithelial Cell Adhesion Molecule, epidermal growth factor recep-
tor) and for proliferation status (Ki67).
Results: CTCs were detected using ISET in 32 of 40 (80%) patients
compared with 9 of 40 (23%) patients using CellSearch. A subpop-
ulation of CTCs isolated by ISET did not express epithelial markers.
Circulating tumor microemboli (CTM, clusters of 3 CTCs) were
observed in 43% patients using ISET but were undetectable by
CellSearch. Up to 62% of single CTCs were positive for the
proliferation marker Ki67, whereas cells within CTM were nonpro-
liferative.
Conclusions: Both technology platforms detected NSCLC CTCs.
ISET detected higher numbers of CTCs including epithelial marker
negative tumor cells. ISET also isolated CTM and permitted mo-
lecular characterization. Combined with our previous CellSearch
data confirming CTC number as an independent prognostic bio-
marker for NSCLC, we propose that this complementary dual
technology approach to CTC analysis allows more complete explo-
ration of CTCs in patients with NSCLC.
Key Words: Circulating tumor cells, Non-small cell lung cancer,
CellSearch, ISET.
(J Thorac Oncol. 2012;7: 306–315)
The detection and characterization of circulating tumorcells (CTCs) in cancer patients offer as yet untapped
potential to further understand the biology of human cancer
metastasis and to identify novel treatment strategies. Recent
advances in technology have paved the way to reproducible
CTC detection and enumeration and begun to reveal their
potential as a real-time, minimally invasive, “virtual biopsy”
(reviewed in Hou et al.1). The robust, semiautomated Cell-
Search platform (Veridex, LLC, Raritan, NJ) has been used to
demonstrate prognostic significance of CTC numbers in pa-
tients with metastatic breast, prostate, and colorectal can-
cers2–7 (reviewed by Krebs et al.8) and subsequently has been
approved by the US Food and Drug Administration as a
prognostic biomarker and as an aid to monitoring treatment
response in these disease types. We recently reported that
CellSearch detection of 5 CTCs (per 7.5 ml of blood) in
patients with advanced non-small cell lung cancer (NSCLC)
is a poor prognostic factor and that a change in CTC number
after a single cycle of standard-of-care chemotherapy predicts
survival outcome.9 However, two-thirds of patients with
stage IV NSCLC had no detectable CTCs, and CTCs were
detectable in less than 5% stage III patients using this tech-
nology platform.
Detection of CTCs using CellSearch is dependent on
tumor cell expression of Epithelial Cell Adhesion Molecule
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(EpCam), an epithelial cell marker. However, the paradigm
of epithelial to mesenchymal transition (EMT) as a predom-
inant mechanism for tumor cell invasion and metastasis raises
the possibility that not all cells in the circulation will express
epithelial markers.10–14 Thus, we hypothesized that the low
prevalence of CTCs detected with the CellSearch technology
in patients with advanced NSCLC, although strongly prog-
nostic, may be due to the loss of EpCam expression. There-
fore, we explored an antigen/EpCAM-independent approach
for the ability to identify CTCs and for the potential to
perform molecular characterization.
ISET(RareCell Diagnostics, Paris, France) is a filter-
based, size exclusion technology capable of isolating CTCs
independently of their expression of any particular marker.
Using this technique, CTCs have been observed previously in
patients with hepatocellular carcinoma, breast carcinoma,
melanoma, and more recently in patients with early-stage,
resectable NSCLC.15–19 In a previous pilot study using ISET,
we noted that CTCs were detectable in patients with ad-
vanced-stage NSCLC, with heterogeneity in both epithelial
(E-cadherin and cytokeratin [CK]) and mesenchymal (N-
cadherin and vimentin) marker expression.20 In addition,
circulating tumor microemboli (CTM; defined as clusters of
cells with three or more nuclei) were identified, whereas
CTM were not detected in our previous evaluation of tumor
cells in 101 patients with NSCLC using CellSearch.9
Our goal was to compare the CellSearch (epithelial
dependent) and ISET (antigen/EpCAM independent) plat-
forms directly for the ability to isolate CTCs in a cohort of
NSCLC patients. Secondary objectives were to explore the
prevalence of CTM in NSCLC patients and to examine
molecular characteristics of cells isolated by filtration, spe-
cifically in relation to their epithelial marker expression and
proliferative status.
PATIENTS AND METHODS
Patient Eligibility and Clinical Characteristics
This was a prospective study conducted at the Christie
Hospital, Manchester, United Kingdom. Patients with che-
mona¨ive, histologically proven NSCLC were eligible. Inclu-
sion criteria included radiologically confirmed stage IIIA or
IIIB/IV disease; World Health Organization performance
status 0–2; age 18 years; and standard-of-care chemother-
apy was to be administered. Patients with a history of prior
malignancy, within the previous 5 years, were excluded. All
patients provided written informed consent according to eth-
ics board approved study protocols. Data were collected for
age, ethnicity, histological subtype, stage of disease, smoking
status, sites of metastases, and treatment received.
Blood Sampling
Peripheral blood (a maximum of 20 ml) samples were
collected up to 1 hour before patients commencing their first
cycle of chemotherapy. Blood (10 ml) was collected in a
CellSave preservative tube (Veridex LLC, NJ), stored at
room temperature, and processed according to standard Veri-
dex protocols within 96 hours of collection. A further 8 to 10
ml was collected in an ethylenediaminetetraacetic acid tube
(Becton Dickinson, NJ), stored at 4°C, and processed by
ISET within 4 hours of collection. Samples were processed in
accordance with the UK Clinical Trials regulations for com-
pliance to Good Clinical Practice for laboratories.21
CTC Detection by CellSearch
Samples were analyzed as previously described.22,23 A
CTC was defined according to the criteria of round to oval
morphology, cell size more than 4 m, 4,6-diamidino-2-
phenylindole (DAPI) positive nucleus, CK positive staining,
and absence of CD45 expression. CTC number is reported
per 7.5 ml of blood. The sensitivity, accuracy, linearity, and
reproducibility of the CellSearch system have been previ-
ously described.22,24 Samples were considered positive for
CTCs if 2 per 7.5 ml of blood were detected as one CTC
has previously been reported as a normal finding.22
CTC Detection by ISET
Blood samples were divided into 1 ml aliquots and
diluted 1:10 with red cell lysis buffer, containing 0.8%
formaldehyde (RareCell Diagnostics), as per manufacturer’s
instructions. Each aliquot was placed into an individual well
of a 10-well ISET filter module (consisting of a polycarbon-
ate track-etched-type membrane punctured by 8-m cylindri-
cal pores, supported beneath a 10-well plastic reservoir).15–18
Filtration was achieved by attaching the module to the ISET
instrument and by applying regulated, gentle suction. Unfil-
tered cells were deposited on a 0.6-cm diameter, circular
“spot” on the membrane beneath each well. After filtration,
each spot was washed once with phosphate-buffered saline
and then the membrane disassembled from the module and
allowed to air dry at room temperature. Filters were subse-
quently stored at 20°C. The sensitivity of the ISET system
has been previously reported as 1 cell per ml,15,17,18 and
similar results were found in our study (see Supplemental
Table 1, http://links.lww.com/JTO/A198). Previous studies
have reported that CTCs are not detectable in blood samples
from healthy donors using the ISET technique.18,19
Identification of CTCs Isolated on ISET Filters
Tumor cells were identified according to absence of the
leukocyte common antigen, CD45, by immunohistochemistry
(IHC) and by their large, hyperchromatic, irregular-shaped
nuclei. Individual spots (each representing 1 ml of filtered
blood) were excised from the filter and placed in pH 6 antigen
retrieval buffer (S1699, Dako) in a 99°C waterbath for 40
minutes. Spots were washed in tris-buffered saline, placed in
0.2% triton for 10 minutes to permeabilize cell membranes,
and exposed for 30 minutes to 3% hydrogen peroxide–
methanol solution to block endogenous peroxidases. Spots
were subsequently washed in water and incubated overnight
at 4°C with monoclonal mouse antihuman CD45 primary
antibody (clone T29/33, Dako) diluted 1:30 in antibody
diluent (S0809, Dako). CD45 staining was achieved with
standard Envision Kits and the Liquid DAB Substrate
Chromagen System according to manufacturer’s instructions
(K5007, Dako) and counterstained with Gill’s hematoxylin.
Spots were mounted on glass slides and scanned at 400
magnification using an Olympus BX52 microscope linked
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with image analysis software (Allegro Plus, Bioview, Re-
hovot, Israel). Staining for CD45 was optimized using cyto-
spins of peripheral blood mononuclear cells as the positive
control and human NSCLC H460 cells (American Type
Culture Collection) as the negative control (Figure 1). H460
cells were spiked into healthy donor blood, and staining was
validated on filtered spots (Figure 2A).
Images were reviewed manually and cells assigned as
tumor if they had (i) negative CD45 expression, (ii) presence
of hyperchromatic nuclei, (iii) irregularly shaped nuclei, (iv)
nuclear size 12 m, (v) nuclear to cytoplasmic ratio more
than 50%, and/or (vi) presence of clusters of CD45 negative
cells containing three or more nuclei with morphology as
described in points (ii) to (v), defined, in this study, as CTM.
Images were reviewed by a Consultant Histopathologist (Dr.
Daisuke Nonaka). For each clinical sample, an average CTC
number was determined from four spots and extrapolated to
7.5 ml for direct comparison with CellSearch (see “Statistical
Considerations” section for determination of optimum num-
ber of spots to stain for reliable enumeration).
FIGURE 1. Biological controls for
immunohistochemistry of circulating
tumor cells (CTCs) isolated by ISET. (A)
Positive-staining controls and (B) nega-
tive-staining controls for each of the
markers used in this study to charac-
terize CTCs/CTM. Control staining was
performed on cell lines or peripheral
blood mononuclear cells (PBMCs),
cytospun onto glass slides. All images
were acquired at 400 magnification
using a Bioview imaging system.
ISET, isolation by size of epithelial
tumor cells; CTM, circulating tu-
mor microemboli.
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FIGURE 2. Exclusion of nontumor cell contaminants on ISET filters and circulating tumor cell (CTC) enumeration strategy. A,
CD45 immunostaining of H460 tumor cells spiked into healthy donor blood and processed through the ISET filtration system
to exclude white blood cells. Filter pores appear dark and circular or cylindrical (black arrows), white blood cells stain brown
due to DAB-substrate reaction (red arrow), and tumor cells appear blue due to the hematoxylin counterstain (blue arrow). B,
Bar chart demonstrating the mean and SE for CTC number depending on the number of spots analyzed. Four spots or more
exhibited the most representative mean CTC value. C, VE-cadherin (CD144) staining on clinical samples processed by ISET to
exclude mature circulating endothelial cells (CECs). CECs exhibited small, round, or oval, pale nuclei with low nuclear-to-cyto-
plasmic ratio and were positive for CD144 (blue arrows). Nuclei appear blue due to hematoxylin counterstain. A cluster of
CECs is shown in the central panel. Filter pores appear dark and circular (black arrows). D, CD45 staining on clinical samples
processed by ISET. Cells with CEC morphology are seen with hematoxylin-stained nuclei (blue arrows). These cells were con-
sidered to be mature CECs on the basis on their morphological similarity with CD144-positive cells (C) and absence of CD45
expression. E, Typical CD45 negative squamous skin cells exhibiting small, round, pyknotic nuclei with abundant cytoplasm
(blue arrows). Filter pores appear dark and circular (exemplified by black arrow). ISET, isolation by size of epithelial tumor
cells.
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Additional Characterization of CTCs on ISET
Filters
To further characterize the captured cells, a series of
filter spots from patient samples were stained for three epi-
thelial markers (EpCam, CKs, and epidermal growth factor
receptor [EGFR]). In addition, the proliferative status of
CTCs and CTM was examined using Ki67. An endothelial
marker (VE-cadherin) was used to exclude the presence of
circulating endothelial cells (CECs). After enumeration,
which used four filter spots per patient, there were up to six
spots remaining per patient for CTC molecular characteriza-
tion (some patients had less depending on the total amount of
blood acquired). To evaluate the full range of markers, a
single filter spot per patient was used for each marker. To
maximize the probability of finding CTCs on a single spot,
only patients with 15 or more CTCs per 7.5 ml of blood by
ISET, equating to an average of 2 CTCs per spot, were
chosen for this aspect of the study. With a limited number of
spots exhibiting this criterion, the numbers of patients eval-
uated for each marker are detailed in Table 1.
Slides from archival tumor biopsies, procured at diag-
nosis, were obtained from four patients with the highest
numbers of CTCs/CTM for comparison of morphology. He-
matoxylin and eosin or Papanicalou staining was performed
by pathologists at the referring hospitals (as part of the
diagnostic process). Slides were scanned at 400 magnifica-
tion using an Olympus BX52 microscope linked with image
analysis software (Allegro Plus, Bioview, Rehovot, Israel) for
direct comparison with ISET-isolated CTCs/CTM.
Cell Culture
Cytospins were prepared from cultured cell lines or
peripheral blood mononuclear cells for use as positive or
negative staining controls for IHC (see Table 1 and Figure 1).
Details of cell culture methodology are included in Supple-
mentary data (http://links.lww.com/JTO/A198).
Statistical Considerations
Concordance between CTC numbers detected by Cell-
Search and ISET were analyzed by Bland-Altman plots.
Pitman’s variance ratio test was used to assess agreement.
Enumeration of CTCs/CTM by ISET is a nonauto-
mated, labor-intensive, and lengthy process. To determine the
minimum number of spots to stain with CD45 for a robust
and representative CTC count per milliliter, 10 ml of healthy
donor blood was collected in ethylenediaminetetraacetic acid
tubes and spiked with 200 NCI-H1299 human lung cancer
cells. Samples were processed according to ISET methodol-
ogy and recovered tumor cells counted on each of the 10
spots, each containing cells trapped from 1 ml of blood. CTC
counts were then calculated from all possible combinations of
spots (i.e., any 1, any 2, any 3, etc.) and mean CTC number
(SE) with 95% confidence intervals calculated for each
(Figure 2B). The total number of cells recovered was 110
(mean  11). Enumerating CTCs from only 1, 2, or 3 spots
exhibited a wide error in mean CTC number estimation.
Analyzing four spots or more provided an accurate estimation
of the true mean (mean  SE  11  0.19, 95% confidence
interval: 10.6–11.4). Replicate experiments confirmed four
spots to provide the most reliable estimation, and therefore
each patient had four spots stained with CD45 for CTC
enumeration, and CTC numbers were extrapolated to 7.5 ml
for comparison with CellSearch.
RESULTS
Patient Demographics
Forty-five patients with NSCLC were recruited to the
study between April 2008 and May 2010. Five patients were
not evaluable for CTC analysis because of insufficient blood
volume for processing by both CellSearch and ISET. Thus,
40 patients with paired blood samples were evaluable for the
study. Patient characteristics are reported in Table 2.
TABLE 1. Number of Membrane Spots (Generated after ISET Blood Filtration) Interrogated with a Range of Antibodies to
Explore Molecular Characteristics of Isolated Tumor Cells
Marker
Number of
Patients Evaluated
(1 Spot Each) Antibody and Concentration Used
Cells Used
as Positive
Control for IHCa
Cells Used
as Negative
Control for IHCa
EpCam 9 Anti-human EpCam; clone VU-1D9, Thermo Scientific; 1:100 SW620 PBMCs
Cytokeratin
(4, 5, 6, 8, 10, 13, 18)
9 Anti-human cytokeratin; clone C-11, Thermo Scientific; 1:100 WiDr PBMCs
EGFR 4 Anti-human epidermal growth factor receptor clone E30, Dako; 1:25 WiDr SW620
VE-cadherin 4 Anti-human endothelial cell marker CD144; Clone 16B1,
eBioscience; 1:50
Huvecs PBMCs
Ki67 14 Anti-human Ki-67; clone MIB-1, Dako; 1:100 H460 PBMCs
IgG control 4 IgG1 control; clone G01, Dako; 1:25 — H1299
Positive- and negative-staining controls are listed.
a SW620 and WiDr are colorectal cancer cell lines; H460 and H1299 are non-small cell lung cancer cell lines, and Huvecs are an endothelial cell line.
ISET, isolation by size of epithelial tumor cells; IHC, immunohistochemistry; PBMCs, peripheral blood mononuclear cells; EGFR, epidermal growth factor receptor; EpCam,
Epithelial Cell Adhesion Molecule.
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CTC Enumeration—CellSearch versus ISET
CTCs were detected using ISET in 32 (80%) patients
out of the 40 evaluated compared with only 9 (23%) patients
using CellSearch. Seven patients had CTCs detected by both
ISET and CellSearch; 2 patients had CTCs detected by
CellSearch only, and 25 patients had CTCs detected by ISET
only. Considering both techniques together, 34 (85%) pa-
tients had detectable CTCs. Numbers of CTCs isolated,
according to disease stage, are detailed in Table 3. The
numbers of CTCs detected by ISET (mean, 71; range,
0–1045) were higher than those detected by CellSearch
(mean, 4; range, 0–78). There was no statistical concordance
between the numbers of CTCs detected by the two techniques
using Bland–Altman analysis (Pitman’s test of difference in
variance, n  40, p  0.001, r  0.988).
CTC Morphology by CellSearch and ISET
Examples of images of cells isolated by CellSearch and
ISET are shown in Figures 3A, B. The size range of cells
detected by CellSearch was 4 to 18 m and by ISET was 12
to 30 m. Cellular morphology was seen with greater clarity
using ISET (in conjunction with hematoxylin staining and
IHC) compared with CellSearch.
Circulating Tumor Microemboli
CTM, which we define here as contiguous clusters of
cells containing three or more nuclei, were observed by ISET
in 15 (38%) of 40 patients including 10 of 23 patients with
stage IV disease, 5 of 12 patients with stage IIIB disease, and
0 of 5 patients with stage IIIA disease (Table 3). There was
no association between histological subtype and the presence
of CTM (Fisher’s exact test p  0.44). The number of intact
nuclei within a single CTM ranged from 3 to 45 and the size
of CTM ranged from 20 to 130 m in diameter. Examples of
typical CTM morphology, confirmed as malignant phenotype
by pathology review, are shown in Figure 3C. Their appear-
ance showed morphological similarity to clusters of cells
within the corresponding primary tumor biopsy/cytology
specimens (Figure 3D). In contrast, no CTM were detected in
any of the 40 patients in parallel blood samples analyzed by
CellSearch.
CECs and Contaminant Skin Cells
Previous studies, using CellSearch technology, have
shown a normal finding of 1 to 20 CECs per milliliter of
blood in healthy individuals and up to 387 CECs per milliliter
of blood in patients with lung cancer.25 Therefore, it is critical
that CECs (reported size 10 m.26) are not falsely desig-
nated as CTCs on ISET filters. This issue was explored by
staining filters for the endothelial marker VE-cadherin
(CD144) that is not expressed on tumor or on white blood
cells. CECs were identified by positive VE-cadherin staining
and exhibited morphology clearly distinct from CTCs/CTM
(Figure 2C). CECs displayed regular-shaped, round, or oval
nuclei, low nuclear-to-cytoplasmic ratio, and paler hematox-
ylin-stained nuclei compared with CTCs/CTM which exhib-
ited irregular-shaped, large, hyperchromatic nuclei with high
nuclear-to-cytoplasmic ratio. On the basis of these morpho-
logical characteristics, mature CECs could be identified and
discounted when using CD45 negative selection alone (Fig-
ure 2D). However, a caveat is that progenitor CECs (a
minority population) can express CD45 weakly and may not
be excluded by negative selection using CD45. Contaminant
skin cells were infrequently detected using ISET and were
readily identified as polygonal-shaped cells with abundant
cytoplasm and small round pyknotic nuclei with absence of
CD45 expression (Figure 2E).
EpCam Staining in CTCs Isolated by ISET
To explore the hypothesis that a proportion of CTCs in
patients with NSCLC may be EpCam negative, a series of
nine patient spots were subjected to EpCam staining by IHC
(positive and negative controls presented in Figure 1). All
CTCs/CTM detected from the nine patients tested were neg-
ative for EpCam expression (Figure 4A). Nonspecific non-
membranous staining was seen in a minority of CTM, but this
staining was considered to be negative (representative image
in Figure 4B). Of the nine patients, six (67%) had no CTCs
detected by CellSearch, whereas ISET detected between 12
and 188 CTCs/7.5 ml of blood. The other three patients had
between 3 and 18 CTCs/7.5 ml of blood detected by Cell-
Search but higher numbers of cells isolated by ISET (17–84
CTCs/7.5 ml of blood).
TABLE 2. Patient Demographics
Characteristic
Patients
(N  40)
Age at baseline, yr
Median 68
Range 46–77
Sex, n (%)
Female 18 (45)
Male 22 (55)
Race, n (%)
White British 39 (97.5)
South Asian 1 (2.5)
Stage at diagnosis, n (%)
IIIA 5 (13)
IIIB 12 (30)
IV 23 (57)
Histological subtype, n (%)
Squamous cell carcinoma (SCC) 15 (37)
Adenocarcinoma 10 (25)
Poorly differentiated 2 (5)
Bronchioloalveolar 2 (5)
NSCLC (not otherwise specified) 11 (28)
Baseline WHO PS, n (%)
0 3 (8)
1 29 (72)
2 8 (20)
Smoking status, n (%)
Current smoker 12 (30)
Ex-smoker 16 (40)
Never-smoker 2 (5)
Not documented 10 (25)
NSCLC, non-small cell lung cancer; WHO, World Health Organization; PS,
performance status.
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Molecular Characterization of CTCs/CTM by
ISET
To further characterize CTCs/CTM identified by
ISET, cells were stained by IHC for the epithelial markers
CKs and EGFR (positive and negative controls shown in
Figure 1). Of the nine patients tested for CK staining, eight
had identifiable CTCs/CTM on the single spot tested. All
CTM, where present, were positive for CK, whereas the
proportion of positive single cells was more heteroge-
neous, ranging from 0 to 90% between patients (represen-
tative images in Figure 4C). Of the four patients tested for
EGFR staining, all had identifiable CTCs/CTM on the
single spot tested. All CTM were again positive for EGFR,
whereas the proportion of positive single cells was heter-
ogeneous, ranging from 0 to 85% between patients (rep-
resentative images in Figure 4D).
TABLE 3. Comparison of the Number of CTCs and CTM Identified by CellSearch and ISET Expressed per 7.5 ml Blood
Patient ID Stage Histology
CTC No. by CellSearch
per 7.5 ml Blood
CTC No. by ISET
per 7.5 ml Blood
CTM No. by ISET
per 7.5 ml Blood
93 IIIA SCC 0 0 0
94 IIIA SCC 1 0 0
57 IIIA NOS 1 4 0
73 IIIA SCC 0 6 0
100 IIIA SCC 0 68 0
Mean  SE 0.4  0.2 15  13.1 0  0
104 IIIB BCA 1 0 0
105 IIIB SCC 0 0 0
89 IIIB Adeno 3 2 0
112 IIIB Poor diff 0 2 0
115 IIIB SCC 0 4 0
113 IIIB Adeno 0 8 0
90 IIIB SCC 0 9 2
86 IIIB NOS 0 60 4
114 IIIB SCC 0 71 13
110 IIIB NOS 0 71 0
91 IIIB Adeno 1 81 6
80 IIIB SCC 0 188 13
Mean  SE 0.4  0.3 41  16.3 3  1.4
18 IV NOS 3 0 0
45 IV SCC 1 0 0
84 IV Adeno 78 0 0
92 IV SCC 0 0 0
118 IV Adeno 0 4 0
17 IV Adeno 0 6 0
106 IV Poor diff 0 6 0
126 IV NOS 0 8 0
107 IV Adeno 18 17 0
82 IV SCC 3 24 4
68 IV Adeno 0 34 0
13 IV NOS 1 38 4
85 IV NOS 30 38 0
25 IV SCC 1 47 6
121 IV SCC 0 49 13
83 IV BCA 0 79 17
127 IV NOS 3 84 0
109 IV NOS 2 116 2
123 IV Adeno 6 131 0
122 IV Adeno 1 137 21
117 IV NOS 0 193 2
116 IV SCC 0 201 26
101 IV NOS 0 1045 39
Mean  SE 6  3.6 98  44.9 6  2.2
Adeno, Adenocarcinoma; BCA, bronchioalveolar; CTCs, circulating tumor cells; CTM, circulating tumor microemboli; NOS, not otherwise specified; Poor diff, poorly
differentiated; SCC, squamous cell carcinoma.
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CTC and CTM Proliferative Status
The proliferative status of CTCs and cells within CTM
was explored using Ki67 in 14 patients (11, stage IV; 2, stage
IIIB; and 1, stage IIIA disease). CTCs and/or CTM were
identified in all cases. The proportion of CTCs staining
positive for Ki67 ranged from 0 to 62% between patients with
no trend according to the disease stage. In contrast, all CTM
were negative for Ki67 staining (Figure 4E).
DISCUSSION
The introduction of the CellSearch platform has en-
abled robust and reliable CTC enumeration in several epithe-
lial tumor types,2–7,22 including NSCLC,9 but the technique is
dependent on the presence of EpCAM expression on CTCs.
With EMT increasingly being reported as an important mech-
anism for cancer cell invasion and metastasis (with the loss of
epithelial markers), this study explored the filtration-based,
antigen-independent ISET system and found that higher num-
bers of CTCs were detected in advanced NSCLC patients
compared with CellSearch. Eighty percent of patients were
positive for CTCs by ISET compared with 23% by Cell-
Search, in support of our hypothesis. A minority of patients
were positive for CTCs by CellSearch but were negative by
ISET, thus changes in protein expression cannot solely ac-
count for the differences in cell capture between the two
systems. Individual CTCs isolated by ISET (18–30 m)
tended to be larger than those isolated by CellSearch (4–18
m), and these physical characteristics may also contribute to
the differences in numbers of CTCs isolated by each system.
One of the most intriguing findings of this study was the
isolation and prevalence of CTM by ISET. Preclinical in vivo
studies have demonstrated that CTM may be an important
mechanism of metastasis with survival advantages over single
cells and greater propensity to seed distant metastates.27–30 Al-
though reported in preclinical models,30–32 studies investigating
CTM in humans have been less forthcoming, mainly due to the
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FIGURE 3. Circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) from patients with non-small cell lung cancer
(NSCLC) using CellSearch and ISET in comparison to primary tumor biopsies. A, Representative images of cells isolated by CellSearch.
CTCs are defined as positive for cytokeratin and DAPI, CD45 negative, and cell size 4 m. B, Representative images of cells isolated by
ISET. CTCs exhibited large, hyperchromatic, irregular-shaped nuclei (identified by hematoxylin counterstain), cell size 12 m, high nu-
clear-to-cytoplasmic ratio, and were CD45 negative. C, Representative images of CTM from NSCLC patients. CTM were CD45 negative,
containing groups of irregularly shaped/pleomophic nuclei and enlarged nucleoli (stained by hematoxylin counterstain). D, Matched pri-
mary tumor biopsies/cytology specimens (top and middle panels stained with hematoxylin and eosin; bottom panel stained with papani-
colau) show striking morphological similarity between groups of cells within tumor and CTM in a paired blood sample (adjacent images
in panel C show CTM from matched patient blood samples). APC, allophycocyanin; CK, cytokeratin; PE, phycoerythrin; ISET, isolation by
size of epithelial tumor cells.
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difficulty in isolating clusters of cells from the blood. However,
anecdotal observations of CTM in clinical samples have been
reported in several cancer types using filtration techniques,15–19
and here CTM were identified in 43% of patients with stage
IIIB/IV NSCLC by ISET. Curiously, CTM were never isolated
by matched samples processed by CellSearch, and this was also
the case in our previous evaluation of 101 patients with ad-
vanced NSCLC by CellSearch.9 A possible explanation may
relate to magnetic beads (employed by CellSearch) having
insufficient capacity to enrich CTM of large physical size (upto
130 m) and weight.
It is important to consider, however, the possibility that
CTM may be a methodological artifact of filtration. The evi-
dence to suggest that this is not the case is that using ISET, CTM
are not seen universally in patients with NSCLC; that cell groups
are not forced together when single cells are spiked into human
blood unless intentionally spiked as groups of cells; and that in
SCLC, CTM are seen in a subset of patients using both ISET and
CellSearch, perhaps because the groups of cells are smaller and
lighter or because they express more EpCam or for both rea-
sons.20,33 Furthermore, CTM in this study showed clear mor-
phological similarities with primary tumor biopsy/cytology
specimens (Figures 3C, D). A number of other studies have
detected CTM using nonfiltration approaches in patients with
renal, prostate, and colorectal cancers.34–36 Stott et al.37 demon-
strated the presence of CTM in patients with advanced NSCLC
or prostate cancer using the novel herringbone-chip which is a
microfluidic mixing device with EpCam-coated chevrons. The
design of this device facilitates the mixing of blood as it passes
through the chip allowing contact and attachment of cells with
the antibody-coated surface. Cells are then directly visualized by
light microscopy, and CTM were identified in a small number of
patients. This lends support to the existence of CTM in patients
with NSCLC as a real entity and not a methodological artifact.
Here we demonstrate that the ISET system is versatile
for the molecular characterization of CTCs and CTM by IHC.
This is an invaluable tool as CTC research moves beyond
CTC enumeration. For example, to identify predictive and/or
FIGURE 4. Molecular characterization of circulating tumor cells (CTCs)/circulating tumor microemboli (CTM) isolated by
ISET. Filtered membrane spots were interrogated with a range of antibodies by immunohistochemistry. A, EpCam staining in
two CTCs and CTM which were all negative for this marker. B, Equivocal EpCam staining within a CTM. C, Cytokeratin stain-
ing was heterogeneous with the images of negative CTCs shown on the left and a positive CTC on the right. D, Variably posi-
tive epidermal growth factor receptor (EGFR) staining in two CTM (left and bottom right images) and a CTC (top right). E,
Ki67 (proliferative status) was positive with nuclear staining in the majority of CTCs (four images shown on the left) and was
negative in all CTM (representative image shown on the right). All images were taken at 400 magnification and representa-
tive images are shown. ISET, isolation by size of epithelial tumor cells.
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pharmacodynamic biomarkers to facilitate drug development,
drug target levels and downstream effects of target inhibition
of a novel agent may be analyzed through serial sampling of
CTCs rather than undertaking serial biopsies, often challeng-
ing to obtain in lung cancer patients. CTC characterization
may also provide novel insight into the biology and mecha-
nisms of metastasis such as EMT. In this study, as proof of
principle that characterization is achievable, IHC was per-
formed on ISET filters on an exploratory basis and cells
interrogated for epithelial markers and proliferative status.
Analysis of EpCam expression on ISET-isolated CTCs/
CTM showed that all cells were negative for this marker,
consistent with lack of CTC detection by CellSearch in the
majority (six of nine) of these patients. In three of nine
patients, CTCs were detected unexpectedly by CellSearch but
in much lower numbers than those isolated by ISET. The
reasons for this may relate to the concept of partial EMT10
(where cells express both epithelial and mesenchymal char-
acteristics) and differential sensitivity of the assays or may be
due to the choice of EpCam antibody used. Analysis of the
epithelial markers EGFR and CK showed that single cells
were heterogeneous for these markers, again supporting the
concept that at least a proportion of circulating cells lack
epithelial characteristics. In addition, a recent study by Hof-
man et al.38 compared CellSearch and ISET for the detection
of CTCs in patients with early-stage, resectable NSCLC.
Similar findings were reported in that higher numbers of
CTCs were isolated by ISET compared with CellSearch, and
a proportion of cells isolated by ISET lacked epithelial
characteristics. Cells within CTM tended to be positive for
EGFR and CK expression, in our study, and that they seem to
maintain their cell–cell interactions within CTM may suggest
that they undergo EMT to a lesser degree than single CTCs.
These hypotheses warrant further interrogation and provide
an impetus to examine further CTC and CTM biology.
As an initial step, we compared the proliferative activity
(by Ki67 staining) of cells within CTM and single CTCs and
revealed that cells within CTM were nonproliferative, in contrast
to a majority subpopulation of solitary CTCs. This suggests that
at the time of sampling, CTM do not represent groups of cells
actively dividing during transit in the blood, rather the lack of
proliferation is more consistent with the hypothesis that cell
clusters break off from the primary tumor, invade the stroma and
local vasculature en mass, and appear in the blood as the product
of collective migration.29 In contrast, up to 62% of single CTCs
stained positively for Ki67. In a previous study of breast cancer
patients, single CTCs were negative for Ki67.39 The difference
in the proliferative status between breast cancer CTCs and lung
cancer CTCs is consistent with disseminated breast cancer cells
existing for many years in the bone marrow with a more
protracted clinical course.39–41 The natural history of lung can-
cer is more rapid and aggressive than the majority of breast
cancers, and the finding of Ki67-positive CTCs may thus mirror
the differential kinetics of disease progression. The biological
and clinical significance of the observed heterogeneity of CTCs/
CTM within and between NSCLC patients remains unclear, but
the opportunity now exists to explore this in further detail.
There are relative advantages and disadvantages to both
CTC isolation techniques used in this study, but when used
together they have a complementary role. ISET isolated higher
numbers of CTCs and CTM than CellSearch, was versatile for
molecular characterization of cells, and has the useful attribute
that it allows storage of filters at 20°C for analysis of a
completed patient cohort of samples at a later time. However,
ISET currently lacks the acknowledged sufficient level of robust
and reliable validation from regulatory agencies as afforded to
CellSearch22 with respect to accuracy and reproducibility for CTC
enumeration, and this currently restricts ISET use for formally
accredited CTC enumeration and prognostication. For this rea-
son, ISET numbers were not correlated with clinical character-
istics or clinical outcomes in this study. Our previous study
showed the strong prognostic utility of CellSearch detected CTC
number and the association of CTCs with stage IV disease and
TABLE 4. Advantages and Disadvantages of the CellSearch
and ISET Techniques for the Isolation of CTCs from Patients
with Non-small Cell Lung Cancer
CellSearch—EpCam-Based ISET—Filtration-Based
Pros
FDA approved for prognostic
use (and as an aid to
monitoring treatment) in
patients with breast, prostate,
and colorectal cancer
Nonantigen dependent—able to
detect wider range and higher
number of cells than
CellSearch
Robust, reliable, reproducible,
semiautomated processing
Able to isolate CTM
Better image quality of cells by
IHC
Stains with CK/CD45/DAPI and
option to stain with one
further antibody, i.e.,
multiparameter staining
Cheaper than CellSearch (but
still expensive)
Nonsize dependent—capable of
detecting smaller CTCs
Cells amenable to interrogation
by IHC, IF, FISH, and
potentially DNA/RNA
extraction for genetic
analyses—potential to explore
CTC biology
Standardized kits Filters can be stored at 20°C
for later analysis
Cons
EpCam dependent—may miss
cells if they have undergone
EMT process (i.e., lack
epithelial markers)
Exploratory—needs further
validation before routine
clinical use
Expensive Manual processing limits
robustness and
reproducibility (but potential to
semi-automate)
Limited ability to further
characterize cells unless
present in high numbers
Size dependent—may miss cells
less than 8 m in size
Numbers of CTCs low in
NSCLC and no CTM
detectable
This study used single-staining
IHC but multiparameter
staining readily achievable by
IHC or IF
FDA, Food and Drug Administration; CK, cytokeratin; FISH, fluorescent in situ
hybridization; IF, immunofluorescence; IHC, immunohistochemistry; CTC, circulating
tumor cell; NSCLC, non-small cell lung cancer; CTM, circulating tumor microemboli;
EMT, epithelial to mesenchymal transition; EpCam, Epithelial Cell Adhesion Molecule.
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presence of liver or bone metastases compared with other sites
of metastatic disease. Advantages and disadvantages of the
CellSearch and ISET techniques are detailed in Table 4.
This study demonstrates the complementary use of two
different technologies to explore and characterize CTCs/CTM in
patients with NSCLC. Our findings highlight a rationale for
using combinations of approaches to delineate how CTCs/CTM
can be evaluated optimally to further understanding of metasta-
sis biology with the goal of improved therapeutics and clinical
management of patients with NSCLC.
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